T
Todd E. DeFor
Researcher at University of Minnesota
Publications - 297
Citations - 19625
Todd E. DeFor is an academic researcher from University of Minnesota. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 64, co-authored 288 publications receiving 17856 citations. Previous affiliations of Todd E. DeFor include City of Hope National Medical Center.
Papers
More filters
Journal ArticleDOI
New Malignancies After Blood or Marrow Stem-Cell Transplantation in Children and Adults: Incidence and Risk Factors
K. Scott Baker,Todd E. DeFor,Linda J. Burns,Norma K.C. Ramsay,Joseph P. Neglia,Leslie L. Robison +5 more
TL;DR: The data reveal that the risk of PTMs, especially solid tumors, continues to increase even 20 years after transplant, necessitating long-term close follow-up for these patients.
Journal ArticleDOI
Searching for unrelated donor hematopoietic stem cells: Availability and speed of umbilical cord blood versus bone marrow
Juliet N. Barker,Timothy P. Krepski,Todd E. DeFor,Stella M. Davies,John E. Wagner,Daniel J. Weisdorf +5 more
TL;DR: The search processes for all pediatric and adult URD transplantation referrals to the University of Minnesota during a period of 1 year confirm that the availability of banked cryopreserved URD UCB grafts allows transplantations for patients with no available BM donor and that URDUCB graft's are available considerably faster than are URD BM grafts.
Journal ArticleDOI
Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units.
Michael R. Verneris,Claudio G. Brunstein,Juliet N. Barker,Margaret L. MacMillan,Todd E. DeFor,David H. McKenna,Michael J. Burke,Bruce R. Blazar,Jeffrey S. Miller,Philip B. McGlave,Daniel J. Weisdorf,John E. Wagner +11 more
TL;DR: An enhanced graft-versus-leukemia effect in acute leukemia patients after transplantation with 2 partially HLA-matched UCB units is revealed.
Journal ArticleDOI
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
Rizwan Romee,Sarah Cooley,Melissa M. Berrien-Elliott,Peter Westervelt,Michael R. Verneris,John E. Wagner,Daniel J. Weisdorf,Bruce R. Blazar,Celalettin Ustun,Todd E. DeFor,Sithara Vivek,Lindsey Peck,John F. DiPersio,Amanda F. Cashen,Rachel L. Kyllo,Amy Musiek,Andras Schaffer,Milan J. Anadkat,Ilana S. Rosman,Daniel D. Miller,Jack O. Egan,Emily K. Jeng,Amy Rock,Hing C. Wong,Todd A. Fehniger,Jeffrey S. Miller +25 more
TL;DR: ALT-803 is a safe, well-tolerated agent that significantly increased NK and CD8+ T cell numbers and function and warrants further investigation to augment antitumor immunity alone and combined with other immunotherapies.
Journal ArticleDOI
Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation
Claudio G. Brunstein,Daniel J. Weisdorf,Todd E. DeFor,Juliet N. Barker,Jakub Tolar,Jo Anne H. Van Burik,John E. Wagner +6 more
TL;DR: Use of ATG in recipients of an NMA preparative regimen warrants close monitoring for evidence of EBV reactivation and potentially preemptive therapy with rituximab.